Treatment of Breast Cancer with Immunogenic Cells Transfected with DNA from Breast Cancer Cells
Annual rept. 1 Jun 1999-31 May 2000
ILLINOIS UNIV AT CHICAGO
Pagination or Media Count:
This investigation was based on the hypothesis that weakly immunogenic, breast cancer- associated antigens, the products of mutant or dysregulated genes in the malignant cells, will be expressed in a highly immunogenic form by a semiallogeneic IL-2 secreting fibroblast transfected with DNA from breast cancer cells. To investigate this question, we transfected LM mouse fibroblasts H2k modified to secrete IL-2 with genomic DNA from breast adenocarcinoma that arose spontaneously in a C3HHe mouse H2k . To increase their nonspecific immunogenic properties, the fibroblasts were also modified before transfection to express allogeneic MHC determinants H-2Kb . Afterward, the IL-2 secreting semiallogeneic cells were cotransfected with DNA from the spontaneous breast neoplasm, along with with a plasmid pHyg conferring resistance to hygromycin. Pooled colonies of hygromycin resistant cells were then tested in C3HHeJ mice for their immunogenic properties against the growth of the breast neoplasm. The results indicated that the tumor-bearing mice immunized with the transfected cells survived significantly longer than mice in various control groups.
- Anatomy and Physiology
- Medicine and Medical Research